Horse tranquilliser trial is awarded $750,000 grant for Parkinson’s research

News

Author: Simge Eva DoganPublished: 26 July 2018

Parkinson's LifePrep: Parkinson's LifeCook: Parkinson's LifeServes:

ketamine

Researchers at the University of Arizona College of Medicine, Tucson, US, will be trialling ketamine – a recreational drug previously used to medicate people with depression – as a treatment for Parkinson’s.

The research – led by Dr Scott Sherman – is being supported with a three-year grant of $750,000 from the Arizona Biomedical Research Commission.

The initial clinical trial will test the effect of ketamine for treating dyskinesia in 10 patients. In addition, the researchers will carry out a separate rodent study to examine how the drug affects the brain.

Dr Scott Sherman, a neurologist at the University of Arizona College of Medicine, said: “Ketamine has been long overlooked. Now it could prove very useful for Parkinson’s patients.”

For information on the latest Parkinson’s research please visit the European Parkinson’s Disease Association website.

For more information on this article click here.

Go Back

Share this story

Comments


Related articles


Parkinson's books

Global update

Three Parkinson’s books to watch out for in 2020

We handpick the most anticipated Parkinson’s reads this year

READ MORE
compulsive behaviour

Special reports

Parkinson’s drugs may lead to compulsive behaviours such as gambling

The study tested 411 people over a three year period

READ MORE
Happy middle aged couple piggybacking on the beach

Health & Fitness

Sex and young onset Parkinson’s

Coping with the impact of Parkinson’s on sexuality at a younger age

READ MORE